Artiva Biotherapeutics IPO

Creates accessible, off-the-shelf NK cell therapies to enhance immune responses against autoimmune conditions and cancer.

NASDAQ: ARTV

Buy

Buy Private Stock

Sign up to invest in private companies like Artiva Biotherapeutics before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Artiva Biotherapeutics before their IPO.

Overview

Artiva Biotherapeutics completed their IPO on July 19, 2024. Now that Artiva Biotherapeutics is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Artiva is a clinical-stage biotechnology company that develops innovative, off-the-shelf natural killer (NK) cell-based therapies designed to harness innate immune functions to treat autoimmune diseases and cancers with safer, more accessible cell therapy options. Its pipeline focuses on non-genetically modified and engineered NK programs that aim to enhance immune responses and improve treatment outcomes across challenging disease areas.

Sector

Healthcare & Life Sciences

Founded

2019

Headquarters

San Diego, CA

Buy

Buy Private Stock

Sign up to invest in private companies like Artiva Biotherapeutics before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Artiva Biotherapeutics before their IPO.

Artiva Biotherapeutics Management Team

Artiva Biotherapeutics people and management – Prior to IPO

  • Board Member
    Laura Stoppel
  • Board Member
    Brian Daniels
  • Board Member
    Dan Baker
  • Board Member
    Diego Miralles
  • Board Member
    Alison Moore
  • CEO, Board Member, President
    Fred Aslan
  • CFO
    Thad Huston
  • Chief Medical Officer
    Subhashis Banerjee
  • Co-Founder
    Peter Flynn
  • COO
    Jennifer Bush
  • CTO
    Christopher Horan

Artiva Biotherapeutics Valuations & Financials

Looking for private company valuations and share price data?

Nasdaq Private Market Data & Intelligence is the private company valuation database covering 4,000+ venture-backed companies with daily pricing, financing history, and secondary market activity. View real-time NPM data on pre-IPO companies including valuations, private company comparable transactions, and historical share price information — the private company due diligence data sources institutional investors rely on.

Similar Companies

Explore companies

like Artiva Biotherapeutics

  • Curology-Logo

    Curology

    Healthcare & Life Sciences

    Offers personalized prescription skin care medications delivered directly to you.

  • Cedar Inc-Logo

    Cedar

    Healthcare & Life Sciences

    The tech platform uses modern intelligence to improve healthcare financial experiences for everyone.

  • Weareresilience-Logo

    Resilience

    Healthcare & Life Sciences

    Operates as technology-focused biomanufacturing company dedicated to broadening access to complex medicines.

  • Cerebral

    Healthcare & Life Sciences

    Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

  • Devoted Health

    Healthcare & Life Sciences

    Provides Medicare Advantage plans to improve older Americans' well-being with comprehensive and family-oriented care.

  • Roman Health Ventures-Logo

    Ro

    Healthcare & Life Sciences

    Healthcare technology for a patient-centric healthcare system.

  • Cityblock Health-Logo

    Cityblock

    Healthcare & Life Sciences

    Tech-driven care provider for communities with complex needs.

  • Insitro-Logo

    insitro

    Healthcare & Life Sciences

    Drug discovery and development company.

  • Elligo Health Research

    Healthcare & Life Sciences

    Connects healthcare sites, sponsors, and patients to streamline clinical trial access through technology and data-driven solutions.

FAQ

Questions?

We have answers

Buy Artiva Biotherapeutics Stock

Artiva Biotherapeutics became publicly traded following its IPO on July 19, 2024, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: ARTV. Before the IPO, Artiva Biotherapeutics stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Artiva Biotherapeutics Stock

Following its IPO on July 19, 2024, Artiva Biotherapeutics shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

 

Artiva Biotherapeutics Stock Price

Following the IPO, Artiva Biotherapeutics stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Artiva Biotherapeutics’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Artiva Biotherapeutics Stock Ticker Symbol

Following its IPO on July 19, 2024, Artiva Biotherapeutics stock now trades on public markets under the ticker symbol NASDAQ: ARTV. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Artiva Biotherapeutics Stock

Following the Artiva Biotherapeutics IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in Artiva Biotherapeutics Stock

Following Artiva Biotherapeutics’s initial public offering on July 19, 2024, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Artiva Biotherapeutics stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Artiva Biotherapeutics Stock Settlement

Since Artiva Biotherapeutics is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Artiva Biotherapeutics IPO

Artiva Biotherapeutics completed its IPO on July 19, 2024, and is now publicly available through major financial sources.